CoChat

Agomelatine Prevents Relapse in Generalized Anxiety Disorder: A 6-Month Randomized, Double-Blind, Placebo-Controlled Discontinuation Study

Stein, Dan J., Ahokas, Antti, Albarran, Cristina, Olivier, Valérie, Allgulander, Christer · 2012 · The Journal of Clinical Psychiatry

The DOI matches its Crossref record.

Abstract

OBJECTIVE: This study evaluated the efficacy and tolerability of agomelatine in the prevention of relapse in patients with generalized anxiety disorder (GAD). METHOD: Patients with GAD (Hamilton Anxiety Rating Scale [HARS] ≥ 22, with items 1 and 2 ≥ 2, item 1 + 2 ≥ 5; Montgomery-Asberg Depression Rating Scale [MADRS] ≤ 16; and < 20% decrease in HARS total score between screening and baseline) who responded to a 16-week course of agomelatine 25-50 mg/d treatment were randomly assigned to receive continuation treatment with agomelatine (n = 113) or placebo (n = 114) for 26 weeks. The main outcome measure was time to relapse during this maintenance period. The estimated risk of relapse was calculated using the Kaplan-Meier method, and groups were compared using a log-rank test stratified for country. The study was undertaken in 31 clinical centers in Canada, Denmark, Estonia, Finland, Hungary, and Sweden from November 2007 to September 2009. RESULTS: During the 6-month maintenance period, the proportion of patients that relapsed during the double-blind period in the agomelatine group (22 patients, 19.5%) was lower than in the placebo group (35 patients, 30.7%). The risk of relapse over time was significantly lower for patients who continued treatment than for those switched to placebo (P = .046, log-rank test stratified for country). Agomelatine was also superior to placebo in preventing relapse in the subset of more severe patients with baseline HARS total score ≥ 25 and CGI-S score ≥ 5. The tolerability of agomelatine was good throughout the study, and there were no differences in discontinuation symptoms after withdrawal of agomelatine in comparison to maintenance on agomelatine. CONCLUSIONS: The present study extends the positive findings of an earlier short-term study of agomelatine in GAD, demonstrating that agomelatine is effective and well-tolerated in the longer-term treatment of this chronic disorder. TRIAL REGISTRATION: www.isrctn.org identifier: ISRCTN38094599.

Overview

Integrity signals

Registry

Crossref · 10.4088/jcp.11m07493

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Still being checked.

Cited by

See all 95

Metadata

Authors
Stein, D. J., Ahokas, A., Albarran, C., Olivier, V., & Allgulander, C.
Affiliations
Groote Schuur Hospital (ZA)
Corresponding author
Stein, Dan J.
Venue
The Journal of Clinical Psychiatry
Published
2012-07-15
Volume
73
Issue
07
Pages
1002-1008
ISSN
0160-6689 (ISSN-L)
OpenAlex
W2005935080
Cited by
94
References
0
Citations by year
2025: 7 · 2024: 4 · 2023: 3 · 2022: 3 · 2021: 7 · 2020: 7 · 2019: 7 · 2018: 4 · 2017: 10 · 2016: 8 · 2015: 14 · 2014: 12 · 2013: 8
FWCI
14.57
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Maternal Mental Health During Pregnancy and Postpartum
Keywords
agomelatine, generalized anxiety disorder, relapse prevention, maintenance therapy, continuation treatment, antidepressant efficacy, tolerability, discontinuation symptoms, melatonin receptor agonists
MeSH terms
Acetamides, Adult, Anxiety Disorders, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Hypnotics and Sedatives, Male, Middle Aged, Naphthalenes, Personality Inventory, Psychometrics, Risk Factors, Substance Withdrawal Syndrome, Kaplan-Meier Estimate, Secondary Prevention, Drug Substitution

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Agomelatine Prevents Relapse in Generalized Anxiety Disorder: A 6-Month Randomized, Double-Blind, Placebo-Controlled Discontinuation Study. https://app.cochat.ai/papers/10.4088/jcp.11m07493
The paper
Stein, D. J., Ahokas, A., Albarran, C., Olivier, V., & Allgulander, C. (2012). Agomelatine Prevents Relapse in Generalized Anxiety Disorder: A 6-Month Randomized, Double-Blind, Placebo-Controlled Discontinuation Study. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.11m07493

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.